drugset / Trial / NCT02438787

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787

Phase 3 Terminated 315 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy of ustekinumab, in adult anti-TNF(alpha) refractory participants with active radiographic axial spondyloarthritis (AxSpA), as measured by the reduction in signs and symptoms of radiographic AxSpA.

Timeline

Start
2015-07-31
Primary completion
2017-08-31
Completion
2017-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ustekinumab Monoclonal antibody 45 mg Subcutaneous
Subject Ustekinumab Monoclonal antibody 90 mg Subcutaneous
Background Golimumab Monoclonal antibody 50 mg Subcutaneous

Indications